Enibarcimab Granted Fast Track Designation for Septic Shock
The Food and Drug Administration (FDA) has granted Fast Track designation to enibarcimab for the treatment of septic shock. Enibarcimab (formerly
Stay updated with breaking news from Stephan Witte. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Food and Drug Administration (FDA) has granted Fast Track designation to enibarcimab for the treatment of septic shock. Enibarcimab (formerly
· With a mortality rate of 20-30% for sepsis and 30-50% for septic shock in developed countries, sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths worldwide· ...
With a mortality rate of 20-30% for sepsis and 30-50% for septic shock in developed countries, sepsis represents an enormous public health burden ...
The Food and Drug Administration (FDA) has granted Fast Track designation to enibarcimab for the treatment of septic shock. Enibarcimab (formerly
Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented todayIn the AdrenOSS-2 trial, the respective patient subgroup had a